Evkeeza® (Evinacumab-dgnb) - CAM 969HB
Background
FDA-Approved Indication: Evkeeza is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) indicated as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) in adult and pediatric patients aged 5 years and older.
Policy (Criteria)
Initial Authorization Criteria
Evkeeza may be considered medically necessary when all of the following criteria are met:
1. Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) confirmed by one of the following:
1.1 Genetic confirmation of two mutant alleles at one or more of the following gene loci:
- LDLR
- APOB
- PCSK9
- LDLRAP1
OR
1.2 Both of the following:
1.2.1 Untreated LDL-C greater than 400 mg/dL
AND
1.2.2 One of the following:
- Xanthoma before 10 years of age
- Evidence of heterozygous familial hypercholesterolemia in both parents
2. Patient is 1 year of age or older
3. One of the following:
- Patient is currently receiving maximally tolerated statin therapy
- Patient is statin intolerant, demonstrated by inability to tolerate at least two statins, including one trial at the lowest starting daily dose, due to intolerable adverse effects or clinically significant liver enzyme or creatine kinase abnormalities
- Patient has a contraindication to all statins
AND
4. One of the following:
- Patient has received ezetimibe (Zetia®) as adjunctive therapy to maximally tolerated statin treatment
- Patient has documented intolerance or contraindication to ezetimibe
- Patient is less than 10 years of age
5. One of the following:
- Patient has received PCSK9 inhibitor therapy (e.g., Repatha® [evolocumab] or Praluent® [alirocumab]) and had an inadequate response
- Prescriber attests that the patient has two LDL receptor-negative alleles with little or no residual receptor activity and therefore is unlikely to respond to PCSK9 inhibitor therapy
- Patient has documented intolerance or contraindication to PCSK9 inhibitor therapy
- Patient is less than 10 years of age
6. Patient will continue traditional lipid-lowering therapy, when clinically appropriate, including:
- Maximally tolerated statin therapy
- Ezetimibe
- Other background lipid-lowering therapies in combination with Evkeeza
7. Dose does not exceed:
- 15 mg/kg administered intravenously once every 4 weeks
8. Prescribed by or in consultation with one of the following:
- Cardiologist
- Endocrinologist
- Hepatologist
- Lipid specialist with expertise in familial hypercholesterolemia
Authorization Duration: 6 months
Reauthorization Criteria
Evkeeza may be reauthorized when all of the following criteria are met:
1. Documentation of positive clinical response to therapy
Examples include one or more of the following:
- Clinically meaningful reduction in LDL-C from baseline
- Achievement of LDL-C treatment goals as determined by the treating specialist
- Reduction in non-HDL cholesterol
- Reduction in apolipoprotein B levels
- Reduction in lipoprotein(a), when applicable
- Improvement in overall lipid profile
2. Patient continues background lipid-lowering therapy when clinically appropriate
Examples include:
- Statin therapy
- Ezetimibe
- Lipoprotein apheresis
- Other adjunctive lipid-lowering therapies unless contraindicated or not tolerated
3. Dose does not exceed:
- 15 mg/kg intravenously every 4 weeks
4. Prescribed by or in consultation with one of the following:
- Cardiologist
- Endocrinologist
- Hepatologist
- Lipid specialist with expertise in familial hypercholesterolemia
Authorization Duration: 12 months
References
- Evkeeza® (evinacumab-dgnb) Prescribing Information. Regeneron Pharmaceuticals, Inc. Current prescribing information.
- Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine. 2020;383(8):711-720.
- U.S. Food and Drug Administration (FDA). EVKEEZA (evinacumab-dgnb) Injection Approval Package.
- National Lipid Association (NLA). Recommendations for the management of familial hypercholesterolemia.
- American Heart Association (AHA). Scientific Statement on Homozygous Familial Hypercholesterolemia.
- European Atherosclerosis Society Consensus Panel. Familial Hypercholesterolaemia in Children and Adolescents.
- GeneReviews®. Familial Hypercholesterolemia.
- National Organization for Rare Disorders (NORD). Homozygous Familial Hypercholesterolemia (HoFH).
Coding Section
| Code |
Number |
Description |
| CPT |
96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour |
|
|
96413 |
Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial substance/drug |
| HCPCS |
J1305 |
Injection, evinacumab-dgnb, 5 mg |
| ICD-10 |
E78.010 |
Homozygous familial hypercholesterolemia (HoFH) |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |